PMID- 35483196
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220603
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 150
DP  - 2022 Jun
TI  - Evaluation of protective effects of methylene blue on cisplatin-induced 
      nephrotoxicity.
PG  - 113023
LID - S0753-3322(22)00412-7 [pii]
LID - 10.1016/j.biopha.2022.113023 [doi]
AB  - Cisplatin (CP) is used to treat various types of cancer. However, its usage is 
      limited due to nephrotoxicity. This study aims to examine the applicability of 
      methylene blue (MB) against CP-induced kidney injuries. In this study, 
      twenty-eight male rats were divided into four groups. Following administration of 
      a single dose of CP (5 mg/kg), animals received intraperitoneal injections (IP) 
      of MB (4 mg/kg) for seven days. In the final phase of the experiment, serum was 
      collected from rats, with blood urea nitrogen (BUN) and creatinine (Cr) levels 
      measured. Hematoxylin-Eosin (H&E) and Masson's trichrome staining were performed 
      to examine histological changes. Immuno-histological staining was used to 
      evaluate caspase-3 protein expression. The results showed that the MB (4 mg/kg) 
      + CP treated rats underwent a lesser weight loss compared to the CP group 
      (p < 0.05 and p < 0.001, respectively). The kidney weight decreased significantly 
      in the CP + MB group compared to the CP group (p < 0.05 and p < 001, 
      respectively). BUN and Cr levels that were increased significantly in the serum 
      of the CP group (p < 0.001) compared to the control group showed no significant 
      increase in the MB + CP group compared to the control group (p = 0.842 and 
      p = 0.989, respectively). There was a significant decrease in kidney tissue 
      injuries in the CP + MB compared to the CP group (p < 0.001). The glomerular size 
      was recovered in the CP + MB group compared to the CP (p < 0.05). The significant 
      increase in the capsular space of the CP group compared to the control group 
      (p < 0.001) was attenuated in the CP + MB. MB restored the histological 
      alterations in the kidneys. Treatment with 4 mg/kg of MB reduced the expression 
      levels of Caspase-3. In conclusion, this study provides evidence concerning the 
      anti-apoptotic roles of MB in CP-induced kidney damage. In conclusion, MB has a 
      positive impact on kidney function.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Usefzay, Obaidullah
AU  - Usefzay O
AD  - Department of Biology, Faculty of Science, Bu-Ali Sina University, Hamadan, Iran.
FAU - Yari, Siamak
AU  - Yari S
AD  - Department of Biology, Faculty of Science, Bu-Ali Sina University, Hamadan, Iran. 
      Electronic address: s.yari@basu.ac.ir.
FAU - Amiri, Parsa
AU  - Amiri P
AD  - Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, 
      Iran.
FAU - Hasanein, Parisa
AU  - Hasanein P
AD  - Department of Biology, School of Basic Sciences, University of Zabol, Zabol, 
      Iran.
LA  - eng
PT  - Journal Article
DEP - 20220425
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - EC 3.4.22.- (Caspase 3)
RN  - Q20Q21Q62J (Cisplatin)
RN  - T42P99266K (Methylene Blue)
SB  - IM
MH  - Animals
MH  - Blood Urea Nitrogen
MH  - Caspase 3/metabolism
MH  - Cisplatin/adverse effects
MH  - Kidney
MH  - *Kidney Diseases/chemically induced/drug therapy/prevention & control
MH  - Male
MH  - Methylene Blue/pharmacology
MH  - Rats
MH  - *Renal Insufficiency/metabolism
OTO - NOTNLM
OT  - Caspase-3
OT  - Cisplatin
OT  - Methylene blue
OT  - Nephrotoxicity
OT  - Rat
EDAT- 2022/04/29 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/04/28 18:17
PHST- 2022/01/15 00:00 [received]
PHST- 2022/04/19 00:00 [revised]
PHST- 2022/04/20 00:00 [accepted]
PHST- 2022/04/29 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
PHST- 2022/04/28 18:17 [entrez]
AID - S0753-3322(22)00412-7 [pii]
AID - 10.1016/j.biopha.2022.113023 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2022 Jun;150:113023. doi: 10.1016/j.biopha.2022.113023. Epub 
      2022 Apr 25.